Fate Therapeutics, Inc. (FATE)
Nasdaq: FATE · Biological Products, (No Diagnostic Substances) · San Diego, CA · filing with the SEC since 2008
Who owns Fate Therapeutics, Inc.
As filed with the SECHolders of 5% or more
1
Redmile Group, LLC holds 14.9% of Common Stock, par value $0.001 per share, as its SCHEDULE 13D/A filed Apr 22, 2026 says.
Directors and officers
14
report now, of 29 people on the record since 2013. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 1 named at left.
Holders of 5% or moreshare of the class, as filed
Redmile Group, LLC
SCHEDULE 13D/A · filed Apr 22, 2026 · Common Stock, par value $0.001 per share · 14.9% in Jul 3, 2025
Goldman Sachs Group Inc.
SCHEDULE 13G/A · filed Aug 14, 2025 · Common Stock, par value $0.001 per share · reported falling below 5%, from 7.4% in May 9, 2025
Blackrock, Inc.
SCHEDULE 13G/A · filed Jul 8, 2026 · Common Stock · reported falling below 5%, from 6.9% in Apr 23, 2025
Schonfeld Strategic Advisors LLC
SCHEDULE 13G/A · filed Aug 14, 2025 · Common Stock, par value $0.001 per share · reported falling below 5%, from 6.8% in May 15, 2025
The Vanguard Group
SCHEDULE 13G/A · filed Mar 26, 2026 · Common Stock · reported falling below 5%, from 7.64% in Jul 29, 2025
What FATE reports owning in othersstakes of 5% or more, and other ties
4 subsidiaries in 3 countries, from the list filed with the 10-K filed Feb 28, 2023.
Insider tradesForm 4
7sales
0purchases
0sales on a scheduled plan
3people selling
$300,000sold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Nov 4, 2025 to Nov 4, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 4, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window3 of 29 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Valamehr Bahram | President and CEO | 3 | $200,000 | 0 | 0 | $0 |
| Tahl Cindy | Chief Legal and Compliance Officer | 3 | $200,000 | 0 | 0 | $0 |
| Adawi Kamal | Chief Financial Officer | 1 | $0 | 0 | 0 | $0 |